Syros Pharmaceuticals (LTS:0LC7) EBITDA Margin %: 0.00% (As of Sep. 2024)


LTS:0LC7 Syros Pharmaceuticals Inc LTS:0LC7
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals EBITDA Margin %?

Syros Pharmaceuticals LTS:0LC7 12 EBITDA Margin % is 0.00% as of Sep. 2024. GuruFocus rates LTS:0LC7 with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Syros Pharmaceuticals's EBITDA for the three months ended in Sep. 2024 was $-4.76 Mil. Syros Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Syros Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.


Syros Pharmaceuticals  (LTS:0LC7) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Syros Pharmaceuticals EBITDA Margin % Related Terms


Syros Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals EBITDA Margin % Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,665.19 -524.82 -339.04 -590.15 -1,582.08

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,016.16 -16,244.30 0.00 0.00 0.00

LTS:0LC7 vs AFMDQ, BTAX, TRVN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Syros Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's EBITDA Margin % falls into.


LTS:0LC7
12GF Score
Syros Pharmaceuticals Inc LTS:0LC7
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Syros Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-157.195/9.936
=-1,582.08 %

Syros Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-4.759/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Syros Pharmaceuticals (LTS:0LC7) has a EBITDA Margin % of 0.00% as of Sep. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syros Pharmaceuticals and its competitors.
Is Syros Pharmaceuticals' EBITDA Margin % too high?
Syros Pharmaceuticals' current EBITDA Margin % is 0.00%. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' EBITDA Margin % compare to AFMDQ and BTAX?
Syros Pharmaceuticals' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syros Pharmaceuticals and its competitors. Syros Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (LTS:0LC7) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Syros Pharmaceuticals (LTS:0LC7), the current EBITDA Margin % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for LTS:0LC7

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price